OpeyemiOlabisi Duke University School of MedicineUnited States

OpeyemiOlabisi
Dr. Olabisi is a physician scientist whose research focuses on APOL1-mediated kidney disease (AMKD). He leverages cell-based models, human stem cell-derived models, and transgenic APOL1 animal model to elucidate the mechanism underlying AMKD. He also conducts NIH-funded community-engaged translational and clinical research (learn more here, www.kidneycareandjustice.com) with the goal of developing innovative cure and prevention of AMKD.
Institution

Day 1 - Sunday April 14, 2024

Time Session
9 a.m.
10:30 a.m.
APOL1 Targeted Therapies: Who to Test and Which Disease to Treat?
Fatiu AbiolaArogundade Chairperson fatiu3@yahoo.comObafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria Nigeria
FernandaSales Luiz Vianna Chairperson fslvianna@gmail.comUniversidade Federal do Rio Grande do SulBrazil
OpeyemiOlabisi Chairperson opeyemi.olabisi@duke.eduDuke University School of MedicineUnited States
  • Ethical Aspects of Race-based Genetic Testing
    AnaIltis Speaker iltisas@wfu.eduWake Forest UniversityUnited States
  • Contribution of ApoL1 Risk Genotype to HIVAN
    SaraladeviNaicker Speaker Saraladevi.Naicker@wits.ac.zaUniversity of the Witwatersrand South Africa
  • Contribution of APOL1 Risk Alleles to Kidney Disease in West Africa
    DwomoaAdu Speaker dwoms@blueyonder.co.ukUniversity of Ghana Medical SchoolGhana
  • Targeting ApoL1: A 12-Year Journey from Genetic Discovery to Phase 2 Trials
    OgoEgbuna Speaker ogo_egbuna@vrtx.comVertex Pharmaceuticals IncUnited States
  • Q and A
Hall C2